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Abstract
Background: Scleroderma is a clinically heterogeneous disease with a complex phenotype. The disease is characterized by
vascular dysfunction, tissue fibrosis, internal organ dysfunction, and immune dysfunction resulting in autoantibody production.
Methodology and Findings: We analyzed the genome-wide patterns of gene expression with DNA microarrays in skin
biopsies from distinct scleroderma subsets including 17 patients with systemic sclerosis (SSc) with diffuse scleroderma
(dSSc), 7 patients with SSc with limited scleroderma (lSSc), 3 patients with morphea, and 6 healthy controls. 61 skin biopsies
were analyzed in a total of 75 microarray hybridizations. Analysis by hierarchical clustering demonstrates nearly identical
patterns of gene expression in 17 out of 22 of the forearm and back skin pairs of SSc patients. Using this property of the
gene expression, we selected a set of ‘intrinsic’ genes and analyzed the inherent data-driven groupings. Distinct patterns of
gene expression separate patients with dSSc from those with lSSc and both are easily distinguished from normal controls.
Our data show three distinct patient groups among the patients with dSSc and two groups among patients with lSSc. Each
group can be distinguished by unique gene expression signatures indicative of proliferating cells, immune infiltrates and a
fibrotic program. The intrinsic groups are statistically significant (p,0.001) and each has been mapped to clinical covariates
of modified Rodnan skin score, interstitial lung disease, gastrointestinal involvement, digital ulcers, Raynaud’s phenomenon
and disease duration. We report a 177-gene signature that is associated with severity of skin disease in dSSc.
Conclusions and Significance: Genome-wide gene expression profiling of skin biopsies demonstrates that the
heterogeneity in scleroderma can be measured quantitatively with DNA microarrays. The diversity in gene expression
demonstrates multiple distinct gene expression programs in the skin of patients with scleroderma.
Citation: Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, et al. (2008) Molecular Subsets in the Gene Expression Signatures of Scleroderma
Skin. PLoS ONE 3(7): e2696. doi:10.1371/journal.pone.0002696
Editor: Geraldine Butler, University College Dublin, Ireland
Received February 13, 2008; Accepted June 17, 2008; Published July 16, 2008
Copyright:  2008 Milano et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by research grants from the Scleroderma Research Foundation to MKC and MLW. Additional support for MLW came from
HHMI Biomedical Research Support Award #76200-560801 to Dartmouth College. SAP and LKG received support from a Hulda Irene Duggan Arthritis Investigator
Award from the Arthritis Foundation to MLW. AM and SAP also received support from NIH Autoimmunity and Connective Tissue Biology Training Grant
(AR007576) from the National Institute of Arthritis, Musculoskeletal and Skin diseases (NIAMS). The sponsors had no role in the design of the experiments, in the
analysis of data or in the preparation and review of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: michael.whitfield@dartmouth.edu
¤ Current address: Optigen Inc., Ithaca, New York, United States of America
Introduction
Scleroderma is a systemic autoimmune disease with a
heterogeneous and complex phenotype that encompasses several
distinct subtypes. The disease has an estimated prevalence of 276
cases per million adults in the United States [1,2]. Median age of
onset is 45 years of age with the ratio of females to males being
approximately 4:1.
Scleroderma is divided into distinct clinical subsets. One subset is
the localized form, which affects skin only including morphea, linear
scleroderma and eosinophilic fasciitis. The other major type is
systemic sclerosis (SSc) and its subsets. The most widely recognized
classification system for SSc divides patients into two subtypes,
diffuseand limited,adistinctionmadeprimarilybythedegreeofskin
involvement [3]. Patients with SSc with diffuse scleroderma (dSSc)
have severe skin involvement [4] often characterized by more rapid
onset and progressive course with fibrotic skin involvement
extending from the hands and arms, trunk, face and lower
extremities. Patients with SSc with limited scleroderma (lSSc) have
fibrotic skin involvement that is typically limited to the fingers
(sclerodactyly), hands and face. Some patients in the limited subset
develop significant pulmonary arterial hypertension, pulmonary
fibrosis or digital ischemia/ulcerations. Although there are certain
diseasecharacteristicsthatdifferentiatethesetwo groups,someof the
severe vascular and organ manifestations occur across groups and
are the cause of significant morbidity and mortality [5].
Disease classification based largely on the extent of skin
involvement does not reflect the true heterogeneity of scleroderma
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diversity among different patients in a way that will provide new
insight into the complexity of the disease. High throughput gene
expression data, combined with clinical phenotypic data, provides a
powerful new tool to probe the underlying biology of scleroderma.
Skin thickening is one of the earliest manifestations of the
disease; it remains the most sensitive and specific finding [8] and is
one of the most widely used outcome measures in clinical trials
[9,10,11]. Several studies have demonstrated that the extent of
skin involvement directly correlates with internal organ involve-
ment and prognosis in SSc patients [12,13,14]. Furthermore,
improvement in Modified Rodnan Skin Score (MRSS) is
associated with improved survival [15]. Probing the gene
expression in this end target organ is likely to yield genes that
will provide clues to pathogenesis and may serve as potential
biomarkers of disease activity. In this study we have measured the
genome-wide patterns of gene expression in skin biopsies from
patients with SSc because skin can provide insights into the
relevant pathological processes in the disease.
DNA microarrays have been used to characterize the changes in
gene expression that occur in dSSc skin when compared to normal
controls [16,17]. Here we extend these findings to show that DNA
microarrays can measure the heterogeneity in scleroderma skin. We
identify molecular subsets among dSSc and define a gene expression
signature that is associated with lSSc. We also identify a subgroup
that contains skin biopsies from patients with dSSc, lSSc and
localized scleroderma (morphea), characterized by a unified gene
expression signature indicative of an early inflammatory response.
Each gene expression subgroup has been mapped to clinical
covariates and biological processes that are modified in the disease.
Results
Previous studies have demonstrated that the skin of patients
with dSSc can be easily distinguished from normal controls at the
level of gene expression [16,17]. Here, we have extended these
findings and tested the hypothesis that we can identify distinct
subsets of scleroderma within the existing clinical classifications by
gene expression profiling of skin biopsies using DNA microarrays.
We studied skin biopsies from 34 subjects: twenty-four patients
with SSc (17 dSSc and 7 lSSc), 3 patients with morphea and 6
healthy controls (Tables 1–2). A single biopsy was analyzed from
a patient with eosinophilic fasciitis (EF). Skin biopsies were taken
from two different anatomical sites for 27 subjects: a forearm site,
and a lower back site. In dSSc, the forearm site was clinically
affected and the back site was clinically unaffected. In lSSc, both
Table 1. Subject clinical characteristics.
Subject Age/Sex Duration, yrs
Skin Score
(0–51)
Raynaud’s
severity (0–10)
Digital Ulcers
(0–3) GI ILD Renal ANA/Scl-70/ACA
dSSc 1 41/F 2 28 - 0 ++ 2 +/+/2
dSSc 2 49/M 2.5 26 3 0 + 22 ND
dSSc 3 33/F 2.5 35 7 0 22 2 +/+/2
dSSc 4 47/F 3 35 7 0 + 22 +/2/2
dSSc 5 52/F 1 10 4 1 + 22 +/+/2
dSSc 6 63/F 0.5 26 10 0 22 2 +/2/2
dSSc 7 42/F 2.5 23 10 3 + 22 ND
dSSc 8 58/M 2 43 7 0 22 2 +/2/2
dSSc 9 56/F 8 21 5 0 ++ 2 +/2/2
dSSc 10 35/F 7 35 8 2 ++ 22 /2/2
dSSc 11 47/F 8.5 30 8 1 ++ 2 +/+/2
dSSc 12 58/M 9 15 5 0 + 22 2 /2/2
dSSc 13 47/F 6 15 3 0 + 22 +/2/2
dSSc 14 49/F 10 15 8 0 2 + 2 +/2/2
dSSc 15 58/F 20 18 2 1 ++ 2 ND
dSSc 16 65/F 10 20 4 0 ++ + ND
dSSc 17 40/F 20 15 2 1 ++ + ND
lSSc 1 67/F 3 8 5 0 + 22 +/2/+
lSSc 2 57/F 2 8 2 0 + 22 +/2/+
lSSc 3 35/F 3 6 6 3 + 22 +/2/2
lSSc 4 63/F 13 8 6 0 2 + 2 +/2/2
lSSc 5 60/F 28 9 6 0 ++ + + /2/2
lSSc 6 55/F 17 9 6 1 ++ 2 +/2/2
lSSc 7 67/F 5 8 5 0 ++ 2 +/+/2
Clinical characteristics of the 25 Systemic Sclerosis subjects from which skin biopsies were taken are shown. Indicated for each subject are the age, sex, disease duration
since first onset of non-Raynaud’s symptoms, modified Rodnan skin score on a 51-point scale, a self-reported Raynaud’s severity score on a 10-point scale, and the
presence or absence of digital ulcers on a 3-point scale. Also indicated are the presence (+) or absence (2) of gastrointestinal involvement (GI), interstitial lung disease
(ILD) as determined by high-resolution computerized tomography (HRCT), and renal disease. The age and sex of subjects with Morphea are: Morph1 (49 yrs, female,
disease duration 16 yrs), Morph2 (54 yrs, female, disease duration 7 yrs), and Morph3 (49 yrs, female, disease duration 4 yrs). The age and sex of healthy control subjects
are as follows: Nor1, 53 yrs, female; Nor2, 47 yrs, female; Nor3, 41, female; Nor4, 26, female; Nor5, 45, male; Nor6, 29, female. ND=Not determined
doi:10.1371/journal.pone.0002696.t001
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provided single biopsies resulting in a total of 61 biopsies. Total
RNA was prepared from each skin biopsy and analyzed on whole-
genome DNA microarrays. In addition, fourteen technical
replicates were analyzed for a total of 75 microarray hybridiza-
tions.
Overview of the gene expression profiles
We identified 4,149 probes whose expression varied from their
median values in these samples by more than 2-fold in at least two
of the 75 arrays and analyzed them by two-dimensional
hierarchical clustering [18]. The resulting sample dendrogram
shows that the samples separate into two main branches
(Figure 1A) that in part stratify patients by their clinical diagnosis.
The branch lengths in the tree are inversely proportional to the
correlation between samples or groups of samples. The diversity in
gene expression among the patients with scleroderma is greater
than previously shown (Figure 1B) [16,17] as distinct subsets of
scleroderma are evident in the gene expression patterns. Some of
these delineate existing classifications, such as the distinction
between limited and diffuse, while others reflect new groups. One
subset of dSSc patients cluster on the left branch (red) and has
gene expression profiles that are distinct from both healthy
controls and patients with lSSc (Figure 1B–1C), while a second
subset of dSSc skin clusters in the middle of the dendrogram tree
(black), and a third set clusters with healthy controls. We found
lSSc samples formed a group in the middle portion of the
dendrogram and could be associated with a distinct, but
heterogeneous gene expression signature that also showed high
expression in a subset of dSSc patients (Figure 1H). LSSc samples
are partially intermixed with normal controls on the right
boundary and with dSSc on the left boundary of the tree,
illustrating that their gene expression phenotype is highly variable
(Figure 1A). Samples taken from individuals with morphea also
grouped together with a gene expression signatures that
overlapped with those of dSSc and lSSc (Figure 1). Although
nodes can be flipped, we have left the nodes of the dendrogram as
originally organized by the clustering software, which places nodes
with the most similar samples next to one another. Although, the
assignment of samples into particular clusters (Table 3) would not
change even if nodes were flipped.
Multiple distinct gene expression programs are evident in each
subgroup. Some of these recapitulate the major themes in our
prior microarray study of dSSc skin [16] while others reflect gene
expression programs not previously observed. A subset of these
biological themes and selected genes are discussed below. The
entire figure with all gene names is available in the supplementary
material (Supplementary Figure S1; Supplementary Data
File S1).
Immunoglobulins typically associated with B lymphocytes and
plasma cells are expressed in a subset of the dSSc skin biopsies
(Figure 1C). Previously we found dense clusters of infiltrating B
cells in dSSc by immunohistochemistry (IHC), indicating that
these genes may be from infiltrating CD20+ B cells rather than
from a small number of infiltrating plasma cells [16].
Previous studies have identified infiltrating T cells in the skin of
dSSc patients [19,20,21,22,23], although an association between T
cell gene expression and dSSc was not observed in our prior study
[16]. A new result from this study is genes typically associated with T
cells are more highly expressed in a subset of the patients
(Figure 1F). These genes include the PTPRC (CD45; Leukocyte
Common Antigen Precursor), which is required for T-cell activation
through the antigen receptor [24,25,26], as well as CD2 [27,28] and
CDW52 [29] that are expressed on the surface of T lymphocytes.
AlsofoundwereCD8A,GranzymeK,GranzymeH,andGranzyme
B that are typically expressed in cytotoxic T lymphocytes
[30,31,32,33,34], and CCR7, which is expressed in B and T
lymphocytes [35]. Genes induced by interferon (IFIT2, GBP1),
genes involved in antigen presentation (HLA-DRB1, HLA-DPA1
and HLA-DMB) and CD74, the receptor for Macrophage
Inhibitory factor (MIF), are also present [36,37,38,39,40]. Genes
typically associated with the monocyte/macrophage lineage, B cells
and dendritic cells (DCs) were also found in this cluster including
Leukocyte immunoglobulin-like receptor B2 and B3 (LILRB2 and
LILRB3; Figure 1F) [41,42]. Finally, genes specific to the
monocyte/macrophage lineage such as CD163 are expressed in
this group of genes (data not shown) [43].
Genes typically associated with the process of fibrosis were co-
expressed with markers of T lymphocytes and macrophages.
These genes showed increased expression in the central group of
samples that included patients with dSSc, lSSc and morphea
(Figure 1E). Included in this set of genes were the collagens
(COL5A2, COL8A1, COL10A1, COL12A1), and collagen triple
helix repeat containing 1 (CTHRC1), which is typically expressed
in vascular calcifications of diseased arteries and has been shown
to inhibit TGF2b signaling [44,45] (Figure 1E). Also found in
this cluster was fibrillin-1 (FBN1). The phenotype of the TSK1
mouse, a model of scleroderma, results from a partial in-frame
duplication of the FBN1 gene and defects in FBN1 are the cause of
Marfan’s syndrome (OMIM: 154700).
A surprising result in this study is the differential expression of a
‘proliferation signature’ (Figure 1D). The proliferation signature is
defined as genes that are expressed only when cells are dividing [46].
We have previously shown that the proliferation signature, originally
identified in breast cancer [47,48], is composed almost completely of
cell cycle-regulated genes [49]. Genes showing increased expression
in this cluster include the cell cycle-regulated genes CKS1B,
CDKS2, CDC2, MCM8, and E2F7 [49]. The existence of a
proliferation signatureisconsistentwith reports demonstrating that a
subset of cells in dSSc skin biopsies show high levels of tritiated
thymidine uptake indicative of cells undergoing DNA replication
[50,51]; a more recent study has shown increased expression of the
cell cycle-regulated gene PCNA in a perivascular distribution [52].
IHC of dSSc skin biopsies with the proliferation marker KI67 also
shows proliferating cells primarily in the epidermis (see below).
Another cluster of genes is expressed at low levels in the dSSc
skin biopsies but at higher levels in all other biopsies, however it is
not clearly associated with a single biological function or process.
Included in this cluster are the genes WIF1, Tetranectin, IGFBP6,
and IGFBP5 found in our original study [16] with similar patterns
of expression (Figure 1G).
Since the skin of lSSc patients does not show any clinical or
histologic manifestations at the biopsy site, it was possible that the
Table 2. Skin samples collected and microarrays hybridized.
Diagnosis Patients Biopsies Microarrays
Diffuse SSc 17 30 38
Limited SSc 7 14 16
Morphea 3 4 5
Normal 6 12 15
Eosinophilic fasciitis 1 1 1
Total 34 61 75
doi:10.1371/journal.pone.0002696.t002
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PLoS ONE | www.plosone.org 3 July 2008 | Volume 3 | Issue 7 | e2696Figure 1. Gene expression signatures in scleroderma. 4,149 probes that changed at least 2-fold from their median value on at least two
microarrays were selected from 75 microarray hybridizations representing 61 biopsies. Probes and microarrays were ordered by 2-dimensional
average linkage hierarchical clustering. This clustering shows that the dSSc, lSSc, morphea samples form distinct groups largely stratified by their
clinical diagnosis. A. The unsupervised hierarchical clustering dendrogram shows the relationship among the samples using this list of 4,149 probes.
Samples names have been color-coded by their clinical diagnosis: dSSc in red, lSSc in orange, morphea and EF in black, and healthy controls (Nor) in
green. Forearm (FA) and Back (B) are indicated for each sample. Solid arrows indicate the 14 of 22 forearm-back pairs that cluster next to one another;
dashed arrows indicate the additional 3 forearm-back pairs that cluster with only a single sample between them. Technical replicates are indicated by
the labels (a), (b) or (c). 9 out of 14 technical replicates cluster immediately beside one another. B. Overview of the gene expression profiles for the
4,149 probes. Each probe has been centered on its median expression value across all samples analyzed. Measurements that are above the median
are colored red and those below the median are colored green. The intensity of the color is directly proportional to the fold change. Groups of genes
on the right hand side indicated with colored bars are shown in greater detail in panels C–H. C. Immunoglobulin genes expressed highly in a subset
of patients with dSSc and in patients with morphea, D. proliferation signature, E. collagen and extracelluar matrix components, F. genes typically
associated with the presence of T-lymphocyes and macrophages, G. Genes showing low expression in dSSc, H. Heterogeneous expression cluster
that is high in lSSc and a subset of dSSc. In each case only a subset of the genes in each cluster are shown. The precise location of each gene in the
cluster can be viewed in Supplemental Figure S1.
doi:10.1371/journal.pone.0002696.g001
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gene expression when compared to normal controls. In fact, lSSc
skin showed a distinct, disease-specific gene expression profile.
This novel finding demonstrates that microarrays are sensitive
enough to identify the limited subset of SSc even when discernable
skin fibrosis was not present. There is a signature of genes that is
expressed at high levels in a subset of lSSc patients, and variably
expressed in dSSc and normal controls (Figure 1H). Included in
this signature is the urotensin 2 receptor (UTS2R). The ligand for
this receptor, urotensin 2, is considered to be one of the most
potent vasoconstrictors yet identified [53,54,55]. This finding
raises the intriguing possibility that this vasoactive peptide is
involved in the vascular pathogenesis of lSSc.
We previously demonstrated that skin biopsies from patients
with early dSSc show nearly identical patterns of gene expression
at a clinically affected forearm site and a clinically unaffected back
site, and the gene expression profiles are distinct from those found
in healthy controls [16]. This finding is confirmed in this larger
cohort of patients analyzed on a different microarray platform. 14
of 22 forearm-back pairs cluster immediately next to one another
indicating that these samples are more similar to each other than
to any other sample (Figure 1A). An additional 3 forearm-back
pairs grouped together with only a single sample between them
(Figure 1A). In total, 17 of 22 (77%) forearm-back pairs show
nearly identical patterns of gene expression. This result holds true
for patients with lSSc even though neither the forearm or back
biopsy sites in lSSc patients are defined as clinically affected [16].
We found 9 out of 14 technical replicates clustered next to one
another. The five technical replicates that did not cluster together
are likely misclassified as a result of noise in the genes selected by
fold change.
Classification of scleroderma using the intrinsic genes
from skin biopsies
A list of genes selected by their fold change alone is not ideal for
classifying samples because they emphasize differences between
samples rather than the intrinsic differences between patients
[47,56]. To select genes that captured the intrinsic differences
between patients, we exploited the observation that the forearm-
back pairs from each SSc patient show nearly identical patterns of
gene expression to select the ‘intrinsic’ genes in SSc. We selected
995 genes with the most consistent expression between each
forearm-back pair and technical replicates, but with the highest
variance across all samples analyzed [47,56] (Supplementary
Data File S2). Each of the 995 intrinsic genes was centered on its
median value across all experiments, and the data clustered
hierarchically in both the gene and experiment dimension using
average linkage hierarchical clustering. The dendrogram summa-
rizes the relationship among the samples and shows their clear
separation into distinct groups (Figure 2A). As a direct result of our
gene selection, all forearm-back pairs cluster together and all
technical replicate hybridizations cluster together when using the
intrinsicgenes.Sampleidentifiershavebeencoloredaccordingtothe
patient diagnosis: dSSc is red, lSSc is orange, morphea and EF are
black, and normal controls are green (Figure 2A). The dendrogram
has been colored to reflect the signatures of gene expression that are
an inherent feature of the biopsies (Figure 2A–C).
The gene expression signatures further subdivide samples within
existing clinical groups. We find a consistent set of genes that are
highly expressed in a subset of the dSSc samples, which occupy the
left branch of the dendrogram tree (Figure 2D). These groups
have been labeled diffuse 1 (Figure 2A; blue branches) and diffuse
2( Figure 2A; red branches) as they consistently cluster as two
separate groups (c.f. Figures 1 and 2) and have distinct
signatures of gene expression. The most consistent biological
program expressed across the diffuse 1 and diffuse 2 scleroderma
samples is that of proliferation (Figure 2D). We refer to this group
broadly as Diffuse-Proliferation. A second group contains dSSc, lSSc
and morphea samples on a single branch of the dendrogram tree
(Figure 2A, purple branches). The genes most highly expressed in
this group are those typically associated with the presence of
inflammatory lymphocyte infiltrates as described above and this
group has thus been labeled the Inflammatory group (Figure 2F). A
third group contains primarily lSSc samples (Limited, orange
branches, Figure 2A), which has low expression of the
proliferation and T cell signatures but has high expression of a
distinct signature found heterogeneously across the samples
Table 3. Cluster assignments using the scleroderma intrinsic
genes.
Patient Cluster 3.0 Sig Cluster Consensus Cluster Assignment
Identifier Assignment (p,0.001) K=4 K=5 K=6
dSSc2 * Diffuse 1 1 [1 or 3] [1 or 5] [1 or 5]
dSSc12 Diffuse 1 1 1 1 1
dSSc1 Diffuse 2 1 1 1 1
dSSc10 Diffuse 2 1 1 1 1
dSSc11 Diffuse 2 1 1 1 1
dSSc15 Diffuse 2 1 1 1 1
dSSc16 Diffuse 2 1 1 1 1
dSSc17 Diffuse 2 1 1 1 1
dSSc3 Diffuse 2 1 1 1 1
dSSc4 Diffuse 2 1 1 1 1
dSSc9 Diffuse 2 1 1 1 1
dSSc8 * Inflammatory [5] 2 2 2
dSSc5 Inflammatory 2 2 2 2
dSSc6 Inflammatory 2 2 2 2
lSSc6 Inflammatory 2 2 2 2
lSSc7 Inflammatory 2 2 2 2
Morph1 Inflammatory 2 2 2 2
Morph2 Inflammatory 2 2 2 2
Morph3 Inflammatory 2 2 2 2
lSSc1 Limited 4 4 4 4
lSSc4 Limited 4 4 4 4
lSSc5 Limited 4 4 4 4
Nor1 Limited 4 4 4 4
lSSc2 Normal-like 3 4 4 4
Nor2 Normal-like 3 4 4 4
Nor3 Normal-like 3 4 4 4
dSSc14 Normal-like 3 3 3 3
dSSc7 Normal-like 3 3 3 3
lSSc3 Normal-like 3 3 3 3
Nor4 Normal-like 3 3 3 3
Nor5 Normal-like 3 3 3 3
Nor6 Normal-like 3 3 3 3
dSSc13 * Unclassified 1 [4] [4] [4]
EF * Unclassified 1 1 1 [6]
*Inconsistently classified
doi:10.1371/journal.pone.0002696.t003
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PLoS ONE | www.plosone.org 5 July 2008 | Volume 3 | Issue 7 | e2696Figure 2. Cluster analysis using the scleroderma intrinsic gene set. The 995 most ‘intrinsic’ genes selected from 75 microarray hybridizations
analyzing 34 individuals. Two major branches of the dendrogram tree are evident which divide a subset of the dSSc samples from all other samples.
Within these major groups are smaller branches with identifiable biological themes, which have been colored accordingly: blue for diffuse 1, red for
diffuse 2, purple for inflammatory, orange for limited and green for normal-like. Statistically significant clusters (p,0.001) identified by SigClust are
indicated by an asterisk (*) at the lowest significant branch. A. Experimental sample hierarchical clustering dendrogram. Black bars indicate forearm-
back pairs which cluster together based on this analysis. B. Scaled down overview of the intrinsic gene expression signatures. C. Limited SSc gene
expression cluster. D. Proliferation cluster. E. Immunoglobulin gene expression cluster. F. T-lymphocyte and IFNc gene expression cluster. The full
figure with all gene names can be viewed in Supplemental Figure S2.
doi:10.1371/journal.pone.0002696.g002
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controls (green branches, Figure 2A) also contains samples from
one patient with a diagnosis of dSSc and a patient with lSSc. This
group has been labeled Normal-like, since the gene expression
signatures in these samples more closely resemble and cluster with
normal skin.
Significance and reproducibility of intrinsic clustering
To examine the robustness of these groups, we performed two
separate analyses: Statistical Significance of Clustering (Sig-
Clust)[57] and consensus clustering [58]. SigClust analysis was
performed with the 995 intrinsic genes. At a p-value,0.001 we
find five statistically significant clusters. The four major groups of
diffuse-proliferation, inflammatory, limited and normal-like groups are
each found to be statistically significant (Figure 2A); samples of
patient dSSc8 form a statistically significant group of their own in
the SigClust analysis (Table 3). Thus, the major groups identified
in the hierarchical clustering using the 995 intrinsic genes are
statistically significant and cannot be reasonably divided into
smaller clusters with the current set of data. The two branches
within the diffuse-proliferation group do not reach statistical
significance in this analysis even though there are identifiable
differences in their gene expression profile.
To perform a second validation of the intrinsic groups, we used
consensus clustering [58], which performs a K-means clustering
analysis on randomly selected subsets of the data by resampling
without replacement over 1,000 iterations using different values of
K. Figure 3A shows the consensus over 1,000 iterations for K=4,
5 and 6. To determine the number of clusters present in the data,
we examined the area under the Consensus Distribution Function
(CDF; Figure 3B). The point at which the area under the CDF
ceases to show significant changes indicates the probable number
of clusters (Figure 3C). The largest change occurs between three
and four clusters with a slight change between four and five
clusters (Figure 3C).
Based on this analysis and the SigClust analysis, we propose that
there are approximately four to five statistically significant clusters in
the data. The statistically significant cluster assignments from both
SigClust and consensus clustering are summarized in Table 3.
These are (1) Diffuse-proliferation comprised completely of patients
with dcSSc, (2) Inflammatory, which includes a subset of dSSc, lSSc
and morphea, (3) Limited, characterized by the inclusion of lSSc
patients and (4) Normal-like, which includes five of six healthy controls
along with two dSSc and one lSSc patients. Notably, three samples
are not consistently classified into the primary clusters. These are:
dSSc2 which is assigned to the either the diffuse-proliferation, normal-like
or into a single cluster by itself, dSSc13 which is assigned to either
diffuse-proliferation or the limited groups, and the patient EF which
clusters either on the peripheral edge of the diffuse-proliferation cluster
or is assigned to a cluster by itself.
To determine how sensitive the clustering was to the selection of
the intrinsic genes, we analyzed the clustering results using a larger
list of 2071 intrinsic genes and compared that clustering to that
obtained with 995 intrinsic genes (Supplemental Figure S3).
Although we find slight differences in the ordering of the samples,
the major subsets of diffuse-proliferation, inflammatory, and limited are
again identified. The Normal-like group is split onto two different
branches using this larger set of genes. Samples that show
inconsistent clustering are from patient dSSc2, dSSc8, dSSc13,
and the single array for patient EF. The samples for each of these
patients were also inconsistently classified in the SigClust and
consensus clustering analysis using the 995 intrinsic gene set.
Principal Component Analysis (PCA) was used to confirm the
samplegrouping found byhierarchical clustering. PCA isan analytic
technique used to reduce high dimensional data into more easily
interpretable principal components by determining the direction of
maximum variation in the data [59]. The 995 intrinsic genes were
analyzed by PCA using the MultiExperiment Viewer (MeV)
software [60]. The first and second principal components that
capture the most variability in the data (Figure 3D), and the first
and third principle components (Figure 3E) have been plotted in 2-
dimensional space. The 2D projection shows that the samples group
in a manner similar to that found by hierarchical clustering analysis:
normal controls and limited samples group together and the two
different groups of diffuse scleroderma group together (Figure 3D).
Notably, the first and second principal components (Figure 3D)
separate the diffuse-proliferation,t h einflammatory and the normal-like/
Limited groups. When the first and third principal components are
analyzed (Figure 3E) we find that the distinction between dSSc group
1 and dSSc group 2 is clearly delineated, as is the distinction between
normal-like and limited. The PCA analysis providesfurtherevidence,in
addition to our hierarchical clustering analysis, that the gene
expression groups are stable features of the data.
Biological processes differentially expressed in the
intrinsic groups
In order to systematically investigate the biological processes
found in the gene expression profiles of SSc, we created a module
map using Genomica software [61,62] (Figure 4A). A module map
shows arrays that have co-expressed genes that map to specific gene
sets. In this case, each gene set represents a specific biological process
derived from Gene Ontology (GO) Biological process annotations
[63], or from previously published microarray datasets [49,64].
Modules with significantly enriched genes (p,0.05, hypergeo-
metric distribution) and corrected for multiple hypothesis testing
with an FDR of 0.1% are shown (Figure 4A). Expressed among
the group diffuse-proliferation are the biological processes of
cytokinesis, cell cycle checkpoint, regulation of mitosis, cell cycle, DNA repair,
S phase, and DNA replication, consistent with the presence of dividing
cells. Decreased in this group are genes associated with fatty acid
biosynthesis, lipid biosynthesis, oxidoreductase activity and decreased
electron transport activity. The decrease in genes associated with fatty
acid and lipid biosynthesis is notable given the loss of subcutaneous
fat observed in dSSc patients [4].
Expressed in the inflammatory group are biological processes
indicative of an increased immune response, including the GO
biological processes of immune response, response to pathogen, humoral
defense, lymphocyte proliferation, chemokine binding, chemokine receptor activity,
and response to virus (Figure 4A). Biological processes of icosanoid and
prostanoid metabolism, which represents synthesis of prostaglandin lipid
second messengers, have been associated with immune responses
[65], found to be highly expressed in rheumatoid arthritis [66,67,68]
and associated with severity in collagen-induced arthritis in mice
[69,70]. Also expressed in this group are processes associated with
fibrosis including trypsin activity, collagen and extracellular matrix. The full
figurewith all differentially expressed biologicalprocesses is available
as Supplemental Figure S4.
In order to better define the proliferation signature observed, we
created gene sets representing the genes periodically expressed in
the human cell division cycle as defined by Whitfield et al. [49]
(Figure 4B). Gene sets were created that included the genes with
peak expression at each of the five different cell cycle phases, G1/
S, S, G2, G2/M and M/G1 [49]. The enrichment of each of these
five gene sets was statistically significant (p,0.05 using the
hypergeometric distribution) and more highly expressed in the
diffuse-proliferation group (Figure 4B).
To better characterize the lymphocyte infiltrates we generated
gene sets representing lymphocyte subsets using results reported by
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lymphocytes and DNA microarray hybridization, the genes
specifically expressed in different lymphocyte subsets were
identified. Subsets included T cells (total lymphocyte and
CD8+), B cells, and granulocytes. We found four of these gene
sets, B cells, T cells, CD8+ T cells and granulocytes, to have a
statistically significant over-representation in the inflammatory group
(Figure 4B). This suggests the gene expression signature
expressed in this group is determined by the presence of infiltrating
lymphocytes and specifically implies the infiltrating cells include T
Figure 3. Robustness of sample classification. The robustness of the sample classifications was analyzed by consensus clustering, which uses
multiple iterations of K-means clustering with random restart. 500 subsets of the data were sampled without replacement. The results of consensus
clustering and Principal Component Analysis (PCA) applied to the 75 arrays and 995 intrinsic genes are shown. A. Consensus matrices are shown for
K=4, 5 and 6. Cluster numbers are shown and cluster assignments are summarized in Table 3. B. Empirical consensus distribution function (CDF) plots
corresponding to K=2,3,4…10. The ideal number of clusters can be identified when the area under the curve shows minimal increases with
increasing K. C. Proportion increase D(K) in the area under the CDF. D. PCA was performed using TIGR MeV software; principal components 1 and 2
are plotted in 2-dimensional space. Samples (points in space) have been colored according Figure 2. Normal-like are green, limited orange, diffuse-
proliferation in red and inflammatory in black. Circles indicate groups of samples distinguished by the top two principal components. E. Principal
components 1 and 3 were plotted in two-dimensional space and show distinction between two groups within the diffuse-proliferation, normal-like
and limited scleroderma.
doi:10.1371/journal.pone.0002696.g003
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expression signature representative of macrophages or dendritic
cells in this analysis, the macrophage marker CD163 is highly
expressed in this group, suggesting innate immune responses may
play an important role in disease pathogenesis.
Immunohistochemistry (IHC)
In order to verify that the gene expression reflected increased
numbers of infiltrating lymphocytes or proliferating cells, we
performed IHC for T cells (anti-CD3), B cells (anti-CD20) and
cycling cells (anti-KI67). Summarized in table 4 is a full
Figure 4. Scleroderma Module Map. A. Module map of the Gene Ontology (GO) Biological Processes differentially expressed among the
scleroderma samples is shown. Each column represents a single microarray and each row represents a single GO Biological process. Patient samples
are organized as described in Figure 2. Only modules that were significantly enriched (minimum 2-fold change, p,0.05) on at least 4 micoarrays are
shown. The average expression of the gene hits from each enriched gene set is displayed here. Only gene sets that show significant differences after
multiple hypothesis testing were included. Select GO biological processes are shown. The entire figure with all biological processes can be viewed in
Supplementary Figure S4. B. Module map using gene list created from an experimental identification of all cell cycle-regulated genes [49] and
genes found to be expressed in specific lymphocyte subsets [64].
doi:10.1371/journal.pone.0002696.g004
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fields of all biopsies analyzed by IHC, with the observer blinded to
disease state. All IHC images for all three markers are available as
supplemental figure S5. Analysis of biopsies from each of the
major intrinsic groups confirmed the results found in the gene
expression signatures. The presence of infiltrating T cells was
confirmed in the inflammatory group (Table 4). The largest
numbers of T cells were found in perivascular and perifollicular
distributions, as well as in the dermis, of two dSSc patients (dSSc5,
dSSc6) assigned to the inflammatory group (Table 4). IHC was also
performed on skin biopsies from two patients with morphea
(Morph1, Morph 3) and each showed large numbers of infiltrating
T cells. Only a small number of T cells were observed in two
healthy controls analyzed (Nor2 and Nor3). A slight increase in T
cells was observed in a perivascular distribution in the four patients
assigned to diffuse-proliferation (dSSc1, dSSc2, dSSc11, dSSc12;
Table 4), which had a lower expression of the T cell signature.
Few CD20+ B cells were observed in the SSc skin biopsies. The
immunoglobulin gene expression signature was observed in eight
diffuse patients (dSSc1, dSSc3, dSSc6, dSSc7, dSSc8, dSSc10,
dSSc11, dSSc12) and one limited patient (1SSc7; Figure 2F). Of
the six patients analyzed by IHC (dSSc1, dSSc2, dSSc5, dSSc6,
dSSc11, dSSc12), two samples (dSSc1and dSSc12) showed small
numbers of CD20+ B cells.
The presence of the proliferation signature is correlated with an
increase in the mitotic index or number of dividing cells in
microarray studies of cancer [46,47,48,49,71]. To confirm the
presence of proliferating cells in the dSSc skin biopsies, we
performed IHC staining for KI67, a standard marker of cycling
cells. Analysis of skin from healthy controls (Nor2, Nor3), morphea
(Morph1, Morph3), and diffuse patients in the inflammatory group
(dSSc5, dSSc6), showed no proliferating cells in the dermis, and a
small numbers of proliferating cells surrounding dermal append-
ages and in the epidermal layer (Table 4). In contrast, analysis of
the skin from four patients in the diffuse-proliferation subgroup
(dSSc1, dSSc2, dSSc11 and dSSc12) showed higher numbers of
proliferating cells primarily in the epidermis (Table 4). Therefore,
we conclude that the proliferation signature is likely the result of an
increased number of proliferating cells in the epidermal compart-
ment of the SSc skin biopsies. The identity of these cells is very
likely to be keratinocytes.
Intrinsic gene expression maps to identifiable clinical
covariates
To map the intrinsic groups to specific clinical covariates,
Pearson correlations were calculated between the gene expression
of each of the 995 intrinsic genes and different clinical covariates.
Shown are the results for three different covariates: the modified
Rodnan skin score (MRSS; 0–51 scale), a self-reported Raynaud’s
severity score (0–10 scale), and the extent of skin involvement
(dSSc, lSSc and unaffected). Each group was analyzed for
correlation to each of the clinical parameters listed in Table 1;
only the significant associations are shown. Figure 5A shows the
gene expression patterns of the 995 intrinsic genes with each row
representing a microarray and each column representing a gene.
Pearson correlation coefficients were calculated between each of
the clinical parameters and the expression of each gene. The
moving average (10-gene window) of the resultant correlation
coefficients is plotted for MRSS (Figure 5B), Raynaud’s severity
(Figure 5C) and degree of skin involvement (Figure 5D). Areas
of high positive correlation between a clinical parameter and the
expression of a group of genes indicate that increased expression of
those genes is associated with an increase in that clinical covariate;
a negative correlation indicates a relationship between a decrease
in expression of the genes and an increase in a clinical covariate.
Areas of high positive or high negative correlation are
highlighted in three different panels (Figure 5B–D, Regions I–
III). Each of the three clinical covariates shows high positive
correlations to a subset of gene expression signatures. Most
notably, the MRSS skin score shows a high positive correlation to
the ‘proliferation signature’ (Figure 5B, region II) with correla-
tions ranging from 0.5 and 0.6. This signature is highly expressed
in diffuse-proliferation samples but has low expression in the
inflammatory group. The Raynaud’s severity score has a high
positive correlation to genes expressed at higher levels in the limited
group and heterogeneously expressed in patients with dSSc
Table 4. Immunohistochemical staining for KI67 and CD3 in the intrinsic subsets.
Patient Assignment
a KI67 Append KI67 Epiderm KI67 Derm CD3 Append CD3 Epiderm CD3 Derm
Nor2 Normal-like 10 11 0 14 0 3
Nor3 Normal-like 0 11 0 22 0 0
Normal-like
b 51 1 01 80 1 . 5
Morph3 Inflammatory 1 13 0 205 18 107
Morph1 Inflammatory 0 21 0 36 5 14
dSSc5 Inflammatory 4 11 0 68 1 5
dSSc6 Inflammatory 7 0 0 83 2 15
Inflammatory 3 11.3 0 98 6.5 35.3
dSSc1 Prolif (2) 4 20 0 56 0 0
dSSc11 Prolif (2) 8 14 0 12 0 7
dSSc2 Prolif (1) 0 22 1 31 0 2
dSSc12 Prolif (1) 2 85 0 55 10 16
Prolif 3.5 35.3 0.3 38.5 2.5 6.3
Shown is the summary of total counts per skin biopsy as determined by IHC staining for KI67, which stains cycling cells, and CD3, which stains T cells. Each biopsy was
also analyzed for CD20 and only a small number of cells were found around dermal appendages for Morph3 (3), dSSc6 (2) and dSSc12 (2). All other samples were
negative for CD20 cells. (Append=dermal appendages (hair follicles, vascular structures, eccrine glands); Epiderm=epidermis; Derm=dermis). a. Intrinsic group to
which each sample was assigned. b. Average of total counts per category.
doi:10.1371/journal.pone.0002696.t004
Subsets of Scleroderma
PLoS ONE | www.plosone.org 10 July 2008 | Volume 3 | Issue 7 | e2696Figure 5. Correlation between gene expression and clinical covariates. A. Shown is the color-coded heatmap of the 75 arrays and 995
intrinsic genes. The graph on the right of the heat map shows disease duration for each sample. Disease duration was set to zero for normal controls
and morphea samples. B. Pearson correlations were calculated between skin score and the expression values for each gene in the list. The moving
average of the Pearson correlation (10-gene window) was plotted. Regions of high negative and high positive correlations to the three different
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correlated with MRSS also show a high positive correlation with
diffuse skininvolvement (Figure 5D, region II). While this signature
associates with diffuse skin involvement, it is important to note that a
subset of dSSc skin biopsies do not express this signature and have
low skin scores. Similarly, the genes that have a high positive
correlation with Raynaud’s severity and a high positive correlation
with the limited group (Figure 5C), which typically has more severe
vascular involvement, are uncorrelated with the diagnosis of dSSc
and are expressed at low levels in healthy control samples
(Figure 5D, region III). Moving averages of the Pearson correlation
between the intrinsic genes and other clinical covariates (digital
ulcers, ILD, or GI involvement) were also calculated but did not
reveal significant regions of positive or negative correlation to the
gene expression profiles (data not shown).
One initial hypothesis wasthat therewould be an obvious trend in
the gene expression data reflecting the progressive nature of SSc in
some patients. To examine this more carefully, disease duration in
years since first onset of non-Raynaud’s symptoms is plotted along
the X-axis of the heat map (Figure 5A, right panel). The mean
disease duration for the diffuse-proliferation group is 8.466.4 yrs,
whereas mean disease duration for the inflammatory group, which
includes dSSc and lSSc, is 6.566.1 yrs. Using a Student’s t-test with
a two-tailed distribution we find that this difference is not statistically
significant. To test the hypothesis that a subset of the patients was
grouping by disease duration, we analyzed the disease duration
between the dSSc patients in the diffuse-proliferation group and the
dSSc patients that were classified as either inflammatory or normal-like
(Table 3). The diffuse-proliferation group has a mean disease duration
of 8.466.4 years, and the dSSc patients in the inflammatory and
normal-like groups have a mean disease duration of 3.263.9 yrs
(Figure 5E, p=0.12, t-test). The difference in the means between
these two groups is clear, but outliers in each reduce the significance
ofthe result. Dropping the two outliersresults inp=0.0042 (unequal
variance two-sample t-test, two-sided)). Therefore, we conclude that
there is a significant association between disease duration and the
intrinsic groups for dSSc samples.
Since no obvious clinical covariate was identified that
differentiated the dSSc group 1 from dSSc group 2, we selected
the genes that most differentiated the two groups. Genes were
selected that differentiated group 1 from group 2 using a non-
parametric t-test implemented in Significance Analysis of Micro-
arrays (SAM) [72]. 329 genes were selected that were differentially
expressed between these two groups with an FDR of 0.19%
(Figure 5F; Supplementary Data File S3). We analyzed these
329 genes for correlation to clinical covariates. Three clinical
covariates were found associated with these two groups. The genes
highly expressed in the dSSc group 2 (9 patients) are highly
correlated with the presence of digital ulcers (DU) and the
presence of interstitial lung disease (ILD) at the time the skin
biopsies were taken. In contrast, dSSc group 1 (2 patients, both
male) did not have DU or ILD at the time of biopsy. Although this
grouping could result simply from stratification by sex, it also may
reflect a true difference in disease presentation. Only 18 of the 329
genes map to either the X or Y chromosomes and thus are
expected to be differentially expressed, suggesting the remainder
may represent biology underlying these groups.
A subset of genes is associated with increased modified
Rodnan skin score
To identify genes associated with MRSS we selected the subset
of genes most highly correlated with each covariate from the
intrinsic list using Pearson correlations. 177 genes were selected
from the 995 intrinsic genes that had Pearson correlations with
MRSS .0.5 or ,20.5. We then used this list of 177 genes to
organize the skin biopsies by average linkage hierarchical
clustering (Figure 6; Supplementary Data File S4). We find
that both forearm and back skin biopsies from 14 patients with
dSSc (mean MRSS of 26.3469.42) clustered onto a single branch
of the dendrogram. All other samples, including the forearm-back
pairs of 4 patients with dSSc (mean MRSS 18.1166.45) clustered
onto a separate branch of the dendrogram. Using a two-tailed
Student’s t-test we find that the difference in skin score between
the two groups of dSSc is statistically significant (p=0.0197).
From this analysis, 62 genes were expressed high levels and 115
genes were expressed at low levels in the patients with the highest
skin score. Genes highly expressed include the cell cycle genes
CENPE, CDC7 and CDT1, the mitogen Fibroblasts Growth
Factor 5 (FGF5), the immediate early gene Tumor Necrosis Factor
Receptor Superfamily member 12A (TNFRSF12A) and TRAF
interacting protein (TRIP). Since skin score is considered to be an
effective measure for disease outcome, this 177-gene group may
contain genes that could be further developed into surrogate
markers for skin score.
Quantitative Real Time PCR
In orderto validate the gene expression inthe major groups found
in this study, we performed quantitative real time PCR (qRT-PCR)
on three genes selected from the intrinsic subsets (Figure 7). These
included TNFRSF12A, which is highly expressed in the dSSc
patients and shows high expression in patients with increased MRSS
(see Figure 6), WIF1, which shows low expression in SSc its
decreased expression is associated with increased MRSS, and
CD8A, which is highly expressed in CD8+ T cells and is highly
expressed in the inflammatory subset of patients. A representative
sampling of patients from the intrinsic subsets was analyzed for
expression of these three genes. Each was analyzed in triplicate and
standardized to the expression of GAPDH.
Each gene is shown with the fold change relative to the median
value for the eight samples analyzed. TNFRSF12A shows highest
expression in the patients with dSSc and the lowest in patients with
limited SSc and normal controls. The three patients with highest
expression are dSSc and include the proliferation group
(Figure 7A). CD8A shows highest expression in the inflammatory
subgroup as predicted by our gene expression subsets (Figure 7B).
WIF1 shows highest expression in the healthy controls with
approximately 4–8 fold relative decrease in patients with SSc
(Figure 7C). The most dramatic decrease is in patients with dSSc
with smaller fold changes in patients with lSSc.
clinical parameters are indicated (regions I–III shaded grey). C. Moving average of the Pearson correlation coefficients (10-gene window) between the
self-reported Raynaud’s severity score and the expression of each gene, D. Moving average of the Pearson Correlations (10-gene window) between
extent of skin involvement and a diagnosis vector (see Methods) for dSSc(red), lSSc (orange) and healthy controls (green). E. Box plot of disease
duration for dSSc patients. The patients included in the diffuse-proliferation group had disease duration of 8.466.4 years. The dSSc patients that fell
into the inflammatory or normal-like groups have disease duration of 3.263.9 yrs (p,0.12, t-test). F. Genes that ideally discriminate ‘Diffuse 1’ and
‘Diffuse 2’ groups were selected using Significance Analysis of Microarrays (SAM). 329 genes were selected with an FDR,1%. Pearson correlation
coefficients were calculated between each clinical parameter and the expression for each gene and plotted as a 10-gene moving window.
doi:10.1371/journal.pone.0002696.g005
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We have used DNA microarrays to determine if the
heterogeneity in scleroderma can be captured quantitatively and
objectively using gene expression profiling. We used an experi-
mental design that has previously been used with great success to
identify molecular subsets in tumors [47,48,56,73,74,75] and now
shows that we can also find subsets in the gene expression patterns
of scleroderma, a disease of completely different etiology but also
characterized by disease heterogeneity.
Our results show that the diversity in the gene expression
patterns of SSc is much greater than demonstrated in two prior
studies of dSSc skin [16,17]. We find evidence for four major
groups, each characterized by a distinct gene expression profile.
The diffuse-proliferation group is composed solely of patients with a
diagnosis of dSSc, the inflammatory group includes patients with
dSSc, lSSc and morphea, the limited group is comprised solely of
patients with lSSc, and the normal-like group includes healthy
controls along with dSSc and lSSc patients. The diffuse-proliferation
group contains two potential subgroups, however, our sample size
is not large enough to draw definitive conclusions regarding their
stability.
It is unlikely that the underlying gene expression groups result
from technical artifacts or heterogeneity at the site of biopsy. First,
we created a standardized sample-processing pipeline, which was
extensively tested on skin collected from surgical discards prior to
beginning this study and included strict protocols that were used
throughout with the goal of eliminating variability in sample
handling and preparation. Second, all gene expression groups
were analyzed for correlation to date of hybridization, date of
sample collection and other technical variables that might have
affected the groupings. Also, heterogeneity at the site of biopsy is
unlikely to account for the findings as the signatures used to classify
the samples were selected by virtue of their being expressed in both
the forearm and back samples of each patient. The inflammatory
group is unlikely to be a result of active infection in patients as
individuals with active infections were excluded from the study.
Finally, the gene expression signatures we found are supported by
both the IHC findings (Table 4) and the quantitative real-time
PCR findings (Figure 7).
We were able to associate our gene expression signatures with
changes in specific cell markers. We have confirmed infiltration of
T cells in the dermis of the ‘inflammatory’ subgroup, and have
confirmed an increase in the number of proliferating cells in the
epidermis in the ‘proliferation’ group. The increase in the number
of proliferating cells in the epidermis could result from paracrine
influences on the resident keratinocytes, possibly activated by the
profibrotic cytokine TGFb. We were not able to find significant
numbers of CD20 positive B-cells.
An open question that remains is how do these gene expression
changes correlate with more specific histological changes in the
skin? Two studies of gene expression in liver [76] and in the brain
[77] have correlated large-scale morphological changes with the
changes in gene expression. In each case it was possible to create a
detailed map linking gene expression to features in detailed
imaging analysis providing addition insight into tumorigenesis. A
comprehensive gene expression study in SSc that combines
detailed histological or morphological analysis of fat changes,
vascular changes and dermal markers, would provide additional
insight into how the gene expression changes correlate with
morphological changes in SSc skin. Unfortunately these analyses
are not possible with our current set of data.
The detection of subsets in the gene expression of SSc raises
questions as to their etiology. Do these subsets represent distinct
groups with stable patterns of gene expression or do the groups
represent different time-dependent phases of the disease? We have
Figure 6. Genes correlated with MRSS. We selected the genes from the 995 intrinsic list that had a correlation greater than 0.5 or less than 20.5
to the MRSS. This list of 177 genes was then used to organize the skin biopsies. Forearm-back pairs from 14 patients with dSSc (mean MRSS of
26.3469.42) clustered onto one branch of the dendrogram tree. The forearm-back pairs of 4 patients with dSSc (Mean MRSS 18.1166.45) clustered
onto a different branch of the dendrogram tree. The difference in skin score between these two groups is statistically significant (p,0.0197).
doi:10.1371/journal.pone.0002696.g006
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expression (Figures 6–7), but only a weak association between
duration of disease and gene expression (Figure 6B). However,
analysis of disease duration in only the dSSc patients raises the
possibility that the groups we have labeled as inflammatory and
normal-like include patients in the early stages of disease, while the
diffuse-proliferation group includes patients with later stage
disease. There is the distinct possibility that patients with the
inflammatory gene expression signature will eventually progress to a
gene expression signature more characteristic of the diffuse-
proliferation group - a hypothesis that can only be addressed
directly in a longitudinal study of a well-defined patient cohort.
The multiple groups observed in our gene expression data may
correspond to patients that will have distinct clinical outcomes. This
is supported by recent work analyzing the relationship between
change in skin score and outcome in a large single center cohort of
225 patients [14]. Using a Latent linear trajectory model, Denton
and coworkers were able to classify 58% of their patients into 1 of 3
subgroups with different skin score trajectories. Each group showed
different progression to clinical endpoints. Survival was lowest in a
group with the highest baseline skin score and showed little
improvement during follow-up. A second group had severe MRSS
butimprovedwithfollow-upandathirdgrouphadlowinitialMRSS
and subsequent improvement. A second study analyzed SSc patients
with anti-topoisomerase I (anti-topo I) antibodies and found patients
could be divided into fivedifferent subgroups based on skinthickness
progression rates [6]. These included three groups of dSSc patients
and two groups of lSSc patients.
This study allows us to then propose two different models that
could account for the gene expression subsets we have found in
scleroderma. The first model is that there are multiple distinct
groups of scleroderma patients, each exhibiting distinct gene
expression profiles. The aberrant gene expression patterns may be
established early in the disease and remain stable during disease
progression. In this case, serial biopsies taken over time would
result in sequential biopsies from the same patient always
remaining in the same group. It would likely be possible to
identify the clinical endpoints and complications to which each
group would progress. The implications are that it may be possible
to predict patient outcome based on their gene expression profile.
The reports of three different groups of diffuse patients with
different outcome trajectories or different skin thickness progress
rates supports this model [6,14].
The second model is that the different gene expression
subgroups represent different disease stages. This is supported in
part by the analysis of disease duration since the first onset of non-
Raynaud’s symptoms between the group we labeled diffuse-
proliferation, and the dSSc patients that were classified as either
inflammatory or normal-like (Figure 5E). There is an obvious trend
toward the patients in the very earliest stages of disease mapping to
the inflammatory group and the latest stage patients mapping to the
diffuse-proliferation group.
The gene expression profiles in scleroderma hold the promise of
identifying markers of disease activity that could be used as
surrogate markers in clinical trials. Therefore, the analysis of skin
biopsies before and after treatment may be useful in testing the
efficacy of novel therapeutics. To this end, we have identified 177
genes that are strongly correlated with the severity of skin disease.
These genes may point to a novel pathway involved in skin fibrosis
that includes TNFRSF12A (Tweak Receptor (TweakR); Fn14),
which is a TNF receptor family member expressed on both
fibroblasts [78] and in endothelial cells [79]. It is induced by FGF1
and other mitogens, including the proinflamatory cytokine TGFb
(J.L.S. and M.L.W., unpublished). In fibroblasts, increased
Figure 7. Quantitative Real Time PCR analysis of representative
biopsies. The mRNA levels of three genes, TNFRSF12A (A), CD8A (B)
and WIF1 (C) were analyzed by Taqman quantitative real time PCR. Each
was analyzed in two representative forearm skin biopsies from each of
the major subsets of proliferation, inflammatory, limited and normal
controls. In the case of TNFRSF12A, patient dSSc11 was replaced by
patient dSSc10, which cluster next to one another in the intrinsic
subsets and show similar clinical characteristics (Table 1). Each qRT-
PCR assay was performed in triplicate for each sample. The level of each
gene was then normalized against triplicate measurements of GAPDH
to control for total mRNA levels (see materials and methods). The
relative expression values are displayed as the fold change for each
gene relative to the median value of the eight samples analyzed.
doi:10.1371/journal.pone.0002696.g007
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fibronectin and vitronectin [78]. TNFRSF12A has also been
shown to play role in angiogenesis [79]. In vitro cross-linking of the
TNFRSF12A in endothelial cells stimulates endothelial cell
proliferation [79], while inhibition prevented endothelial cell
migration in vitro and angiogenesis in vivo. Activation of
TNFRSF12A in human dermal fibroblasts results in increased
production of MMP1, the proinflammatory prostaglandin E2, IL6,
IL8, RANTES and IL10 [80]. The cytoplasmic domain of
TNFRSF12A binds to TRAF1, 2 and 3 [79]. A factor downstream
of the TRAFs, TRIP (TRAF Interacting Protein), is highly
correlated with MRSS. With further refinement, these genes could
serve as surrogate markers for disease severity in scleroderma.
Materials and Methods
Ethics approval was obtained for this study from the University
of California at San Francisco’s Committee on Human Research
(CHR) and from Dartmouth College’s Committee for the
Protection of Human Subjects (CPHS). All subjects signed consent
forms approved by the CHR at the University of California, San
Francisco (UCSF). All patients met the American College of
Rheumatology classification criteria for SSc [8] and were further
characterized as the diffuse (dSSc) [3], or the limited (lSSc) subsets
[1]. LSSc patients had 3 of the 5 features of CREST (calcinosis,
Raynaud’s syndrome, esophageal dysmotility, sclerodactyly and
telangiectasias) syndrome, or had Raynaud’s phenomenon with
abnormal nail fold capillaries and scleroderma-specific autoanti-
bodies. The diffuse systemic sclerosis (dSSc) had wide spread
scleroderma and MRSS ranging from 15 to 35. The lSSc patients
had MRSS ranging from 8 to 12. Patients with undifferentiated
connective tissue disease (UCTD) were excluded from the study.
Skin biopsies were taken from a total of 34 individuals: 17
patients with dSSc, 7 patients with lSSc, 3 patients with morphea
(MORPH), 6 healthy volunteers (NORM) and one patient with
eosinophilic fasciitis (EF) (Table 1). dSSc patients (median age
4969.4 years) were divided into two groups by their disease
duration as defined by first onset of non-Raynaud’s symptoms.
Eight of the dSSc patients had disease duration ,3 years since
onset of non-Raynaud’s symptoms (median disease duration
2.2560.8 years) and nine dSSc patients had disease duration
.3 years since onset of non-Raynaud’s symptoms (median disease
duration 965.3 years). The seven patients with lSSc had a median
disease duration 569.7 years. The three patients with morphea
had median disease duration 766.2 years.
In most cases, two 5-mm punch biopsies were taken from the
lateral forearm, 8 cm proximal to the ulna styloid on the exterior
surface non-dominant forearm for clinically involved skin. Two 5-
mm punch biopsies were also taken from the lower back (flank or
buttock) for clinically uninvolved skin. Thirteen dSSc patients
provided forearm and back biopsies; four dSSc patients provided
only single forearm biopsies. The seven lSSc patients and all six
healthy controls also underwent two 5-mm punch biopsies at the
identical forearm and back sites. Three subjects with morphea
underwent two 5-mm punch biopsies at the clinically affected
areas of the leg (MORPH1), abdomen (MORPH2), and back
(MORPH3).
For each patient, one biopsy was immediately stored in 1.5. mL
RNAlater (Ambion) and frozen at 280uC, a second biopsy was
bisected; half went into 10% formalin for routine histology and
half was fresh frozen. In total, 61 biopsies were collected for
microarray hybridization: 30 from dSSc, 14 from lSSc, 4 from
morphea, 1 eosinophilic fasciitis, and 12 from healthy controls
(Table 2).
RNA was prepared from each biopsy by mechanical disruption
with a PowerGen125 tissue homogenizer (Fisher Scientific)
followed by isolation of total RNA using an RNeasy Kit for
Fibrous Tissue (Qiagen). Approximately 2–5 mg of total RNA was
obtained from each biopsy.
cRNA synthesis, microarray hybridization and data
processing
200 ng of total RNA from each biopsy was converted to Cy3-
CTP (Perkin Elmer) labeled cRNA, and Universal Human
Reference (UHR) RNA (Stratagene) was converted to Cy5-CTP
(Perkin Elmer) labeled cRNA using a low input linear amplifica-
tion kit (Agilent Technologies). Labeled cRNA targets were then
purified using RNeasy columns (Qiagen). Cy3-labeled cRNA from
each skin biopsy was competitively hybridized against Cy5-CTP
labeled cRNA from Universal Human Reference (UHR) RNA
pool, to 44,000 element DNA oligonucleotide microarrays (Agilent
Technologies) representing more than 33,000 known and novel
human genes in a common reference design [81]. Hybridizations
were performed for 17 hours at 65uC with rotation.
After hybridization, arrays were washed following Agilent 60-
mer oligo microarray processing protocols (66 SSC, 0.005%
Triton X-102 for 10 min. at room temperature; 0.16 SSC, 0,
005% Triton X-102 for 5 min at 4uC, rinse in 0.16 SSC).
Microarray hybridizations were performed for each RNA sample
resulting in 61 hybridizations. Fourteen replicate hybridizations
were added, resulting in a total of 75 microarray hybridizations.
Microarrays were scanned using a dual laser GenePix 4000B
scanner (Axon Instruments). The pixel intensities of the acquired
images were then quantified using GenePix Pro 5.0 software.
Arrays were visually inspected for defects or technical artifacts, and
poor quality spots were manually flagged and excluded from
further analysis. Only spots with fluorescent signal at least twofold
greater than local background in both Cy3- and Cy5- channels
were included in the analysis. Probes missing more than 20% of
their data points were excluded, resulting in 28,495 probes that
passed the filtering criteria. The data were displayed as log2 of the
LOWESS-normalized Cy5/Cy3 ratio. Since a common reference
experimental design was used, each probe was centered on its
median value across all arrays.
Selection of intrinsic genes
An intrinsic gene identifier algorithm was used to select a set of
intrinsic scleroderma genes. Detailed methods on the selection of
intrinsic genes are available in [47] and http://genome-www.
stanford.edu/breast_cancer/molecularportraits/. A gene was con-
sidered ‘intrinsic’ if it showed the most consistent expression
between forearm-back pairs and technical replicates for the same
patient, but had the highest variance in expression across all
samples analyzed. The intrinsic gene identifier computes a weight
for each gene, which is inversely related to how intrinsic the gene’s
expression is across the samples analyzed. A lower weight equals a
higher ‘intrinsic’ character. A total of 34 experimental groups were
defined, each representing the 34 different subjects in our study.
Replicate hybridizations for a given patient were assigned to the
same experimental group.
In order to estimate False Discovery Rate (FDR) at a given
intrinsic weight, the analysis was repeated on data randomized in
rows (i.e. across each gene). The FDR at a given weight was
estimated by determining the number of genes that received the
same weight or lower in the randomized data. 995 genes were
selected that had an intrinsic weight ,0.3; in randomized data
3967 genes (calculated from 10 independent randomizations) had
a weight of 0.3 or less, resulting in an FDR of approximately 4%.
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selected with an acceptable FDR, while retaining reproducible
hierarchical clustering of technical replicate samples. Although it is
possible to select a more or less restrictive list of genes with FDRs
of 5% (weight ,0.35; 2071 genes), 3.4% (weight ,0.25; 425
genes) or 2.4% (weight ,0.20; 171 genes), these smaller lists of
genes resulted in less reproducible hierarchical clustering suggest-
ing overfitting (Supplemental Figure S3).
Hierarchical clustering
Average linkage hierarchical clustering was performed in both
the gene and experiment dimensions using either Cluster 3.0
software (http://bonsai.ims.u-tokyo.ac.jp/,mdehoon/software/
cluster/software.htm) or X-Cluster (Gavin Sherlock; http://
genetics.stanford.edu/,sherlock/cluster.html) using Pearson cor-
relation (uncentered) as a distance metric [18]. Clustered trees and
gene expression heat maps were viewed using Java TreeView
Software (http://jtreeview.sourceforge.net/) [82].
Robustness and statistical significance of clustering
The statistical significance of clustering was assessed using
Statistical Significance of Clustering (SigClust) [57] and Consensus
Cluster [58]. SigClust tests the null hypothesis that the samples
form a single cluster. A statistically significant p-value indicates the
data came from a non-Gaussian distribution and that there is more
than one cluster. Two different p-values were used to identify
significant clusters, p,0.01 and p,0.001. The statistical signifi-
cance of the clusters was first assessed at the root node of the tree
derived from hierarchical clustering with the 995 intrinsic genes. If
the cluster was statistically significant, the next node further down
the tree was tested. The process ended when a cluster had a p-
value greater than the established cutoff.
In addition, we analyzed the 995 intrinsic genes using
Consensus Cluster [58]. Consensus Cluster is available through
GenePattern (v.1.3.1.114; [83]). Assessment of sample clustering
was performed by consensus clustering with K clusters (K=2, 3,
4…10) using 1000 iterations with random restart. Samples that
clustered together most often in each of the K clusters received a
correlation value. The resulting consensus matrix was visualized as
a color-coded heat map with varying shades of red, the brighter of
which corresponded to higher correlation among samples
(Figure 3A). Summary statistics are shown, including the empirical
consensus distribution function (CDF) vs. the consensus index value
(Figure 3B). Also shown are the proportion change (DK) under
the CDF for each K=2, 3…10 (Figure 3C). Consensus Cluster
assignments for each sample are summarized in Table 3.
Principal Component Analysis
Principal Component Analysis was performed using Multi-
experiment Viewer (MeV) software version 4.0.01 (http://www.
tm4.org/mev.html; [60]). Data was loaded into MeV as a tab
delimited text file of log2-transformed Cy3/Cy5 ratios. For PCA
analysis [59], missing data were first estimated using K-nearest
neighbors (KNN) imputation with N=4.
Module Maps
Module maps were created using the Genomica software
package [61,62]. Gene sets containing all human Gene Ontology
(GO) Terms were obtained from the Genomica web site (http://
genomica.weizmann.ac.il/; Human_go_process.gxa, created Nov.
20, 2006). Additional custom gene sets representing the human cell
division cycle [49] and lymphocyte subsets [64] were created
specifically for this study. The human cell division cycle gene set
was created from the genes found to periodically expressed in
human HeLa cells [49]. Genes found to show peak expression at
the five different cell cycle phases G1/S, S, G2, G2/M and M/G1
were each put into their own independent gene list. Gene sets
representing different lymphocyte populations, T cells (total
population, CD4+, CD8+), B cells, and granulocytes, were derived
for this study from the genes expressed in isolated lymphocyte
subsets by Palmer and coworkers [64].
All 75 microarray experiments and 28,495 DNA probes were
included in the module map analysis. The 28,495 probes were
collapsed to 14,448 unique LocusLink Ids (LLIDs) [84]. Only gene
sets with at least three genes but fewer than 1000 genes were
analyzed. A gene set was considered enriched on a given array if at
least 3 genes from that set were considered to be significantly up-
regulated or down-regulated (minimum 2-fold change, p,0.05,
hypergeometric distribution) on at least four microarrays. Each
gene set was corrected for multiple hypothesis testing using an
FDR correction of 0.1%.
Correlation to clinical parameters
Pearson correlations were calculated between each clinical
parameter and the gene expression data in Microsoft Excel.
Pearson correlations between the diagnosis of dSSc, lSSc and
healthy controls and the gene expression data were calculated by
creating a ‘diagnosis vector’. The diagnosis vector was created by
assigning a value 1.0 to all dSSc samples and 0.0 to all remaining
samples for the dSSc vector; lSSc and healthy controls were
treated similarly creating a vector for each. Pearson correlations
were calculated between the gene expression vector and the
diagnosis vector for dSSc, lSSc and healthy controls. Correlations
between the gene expression and clinical data were plotted as a
moving average of a 10-gene window.
Immunohistochemistry (IHC)
IHC was performed on paraffin embedded sections at the
University of California, San Francisco in the Immunohistochem-
istry and Molecular Pathology core facility. All immunostaining was
completed via a semi-automated protocol utilizing an automated
immunostainer (DAKO Corp, Carpenteria, CA). Slides were
heated, deparaffinized and then hydrated. Protease digestion was
completed followed by antigen retrieval via pressure cooker as per
standard protocols. After an endogenous peroxidase block with 3%
H202, slides were loaded on to the automated immunostainer. A
primary antibody cycle of 30 min was followed by a secondary
antibody cycle using the ENVISION+ system. Color development
was completedusing DAB followedbycounterstaining with Gills #2
Hematoxylin. Specific conditions for the antibodies utilized were as
follows: anti-CD20 (DAKO) was used at 1:600 for 30 minutes in
citratebuffer(pH 6.0);anti-CD3(DAKO) at 1:400for30 minutes in
Tris buffer (pH 9.0), and anti-Ki67 (MiB1; DAKO) was used at
1:1000 for 30 minutes in Tris buffer (pH 9.0). Marker positive cells
were enumerated by tissue compartment in equal sized images of n
skin biopsies, with the observer blinded to disease state and array
results of the specimens (Table 4).
Quantitative Real-Time PCR. Each quantitative real time
PCR assay [85] was performed with 100–200 ng of total RNA.
Each sample was reverse-transcribed into single-stranded cDNA
using SuperScript II reverse transcriptase (Invitrogen, San Diego,
CA). 96-well optical plates were loaded with 25 ml of reaction
mixture which contained: 1.25 ml of TaqManH pre-designed
Primers and Probes, 12.5 ml of TaqManH PCR Master Mix, and
1.25 ng of cDNA. Each measurement was carried out in triplicate
with a 7300 Real-Time PCR System (Applied Biosystems). Each
sample was analyzed under the following conditions: 50uC for
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60uC for 1 min for 40 cycles. Output data was generated by the
instrument onboard software 7300 System version 1.2.2 (Applied
Biosystems). The number of cycles required to generate a detectable
fluorescence above background (CT) was measured for each sample.
Fold difference between the initial mRNA levels of target genes
(TNFRSF12A, CD8A and WIF1) in our experimental samples were
calculated with the comparative CT method using formula 2
2DDCT
[86] and median centered across all samples analyzed.
Data Access
The full dataset, figures in both red/green and blue/yellow
format, as well as searchable versions of figures 1 and 2 are available
at website maintained by the authors: http://whitfieldlab.dart-
mouth.edu/SScSubsets/. Raw data is available from the UNC
Microarray Database (https://genome.unc.edu/) and has been
deposited to NCBI’s Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/; accession Number: GSE9285).
Supporting Information
Figure S1 Gene expression signatures in scleroderma. 4,149
probes that changed at least 2-fold from their median value on at
least two microarrays were selected from 75 microarray hybrid-
izations representing 61 biopsies. Probes and microarrays were
ordered by 2-dimensional average linkage hierarchical clustering.
This clustering shows that the dSSc, lSSc, morphea samples form
distinct groups largely stratified by their clinical diagnosis. A. The
unsupervised hierarchical clustering dendrogram shows the
relationship among the samples using this list of 4,149 probes.
Samples names have been color-coded by their clinical diagnosis:
dSSc in red, lSSc in orange, morphea and EF in black, and
healthy controls (Nor) in green. Forearm (FA) and Back (B) are
indicated for each sample. Solid arrows indicate the 14 of 22
forearm-back pairs that cluster next to one another; dashed arrows
indicate the additional 3 forearm-back pairs that cluster with only
a single sample between them. Technical replicates are indicated
by the labels (a), (b) or (c). 9 out of 14 technical replicates cluster
immediately beside one another. B. Overview of the gene
expression profiles for the 4,149 probes. Each probe has been
centered on its median expression value across all samples
analyzed. Measurements that are above the median are colored
red and those below the median are colored green. The intensity
of the color is directly proportional to the fold change. Groups of
genes on the right hand side indicated with colored bars are shown
in greater detail in panels C y ¨¢§through H. C. Immunoglobulin
genes expressed highly in a subset of patients with dSSc and in
patients with morphea, D. proliferation signature, E. collagen and
extracelluar matrix components, F. genes typically associated with
the presence of T-lymphocyes and macrophages, G. Genes
showing low expression in dSSc, H. Heterogeneous expression
cluster that is high in lSSc and a subset of dSSc. This figure shows
all gene names associated with the panels in figure 1 and is
designed to be viewed in a digital format only so that one can
zoom in to read the gene names.
Found at: doi:10.1371/journal.pone.0002696.s001 (3.00 MB PDF)
Figure S2 Cluster analysis using the scleroderma intrinsic gene
set. The 995 most ‘intrinsic’ genes selected from 75 microarray
hybridizations analyzing 34 individuals. Two major branches of
the dendrogram tree are evident which divide a subset of the dSSc
samples from all other samples. Within these major groups are
smaller branches with identifiable biological themes, which have
been colored accordingly: blue for diffuse 1, red for diffuse 2,
purple for inflammatory, orange for limited and green for normal-
like. Statistically significant clusters (p,0.001) identified by
SigClust are indicated by an asterisk (*) at the lowest significant
branch. A. Experimental sample hierarchical clustering dendro-
gram. Black bars indicate forearm-back pairs which cluster
together based on this analysis. B. Scaled down overview of the
intrinsic gene expression signatures. C. Limited SSc gene
expression -cluster. D. Proliferation cluster. E. Immunoglobulin
gene expression cluster. F. T-lymphocyte and IFNc gene
expression cluster. This file shows all gene names associated with
the panels in figure 2 and is designed to be viewed in a digital
format only so that one can zoom in to read the gene names.
Found at: doi:10.1371/journal.pone.0002696.s002 (6.69 MB PDF)
Figure S3 Robustness of intrinsic clustering. Hierarchical
clustering was performed with two different sets of intrinsic genes.
A. 995 intrinsic genes (weight ,0.3; 4% FDR), B. 2071 intrinsic
genes (weight ,0.35, 5% FDR). Statistically significant clusters
(p,0.05) as determined by SigClust are indicated by an asterisk
(*). Transparent bars indicate the movement of groups of samples.
The major clusters are recapitulated with this larger set of genes.
Found at: doi:10.1371/journal.pone.0002696.s003 (1.07 MB TIF)
Figure S4 Scleroderma Module Map. Module map of the Gene
Ontology (GO) Biological Processes differentially expressed among
the scleroderma samples is shown. Each column represents a single
microarray and each row represents a single GO Biological
process. Patient samples are organized as described in Figure 2.
Only modules that were significantly enriched (minimum 2-fold
change, p,0.05) on at least 4 micoarrays are shown. The average
expression of the gene hits from each enriched gene set is displayed
here. Only gene sets that show significant differences after multiple
hypothesis testing were included. This figure is best viewed in PDF
format in order to read all modules names.
Found at: doi:10.1371/journal.pone.0002696.s004 (2.41 MB TIF)
Figure S5 Immunohistochemistry for lymphocyte subsets and
proliferating cells in scleroderma skin. Lymphocyte subsets in forearm
biopsies of six dSSc patients, the leg and back specimens of two
morphea patient and forearm samples of two healthy control were
analyzed byimmunohistochemistry. Paraffin sectionswere stained for
T cells (CD3), B cells (CD20) and proliferating cells (KI67).
(Magnification:6200). See table 4 for detailed quantification.
Found at: doi:10.1371/journal.pone.0002696.s005 (9.60 MB TIF)
Data File S1 4,149 probes shown in figure 1 that changed at
least 2-fold from their median value on at least two microarrays
were selected from 75 microarray hybridizations representing 61
biopsies.
Found at: doi:10.1371/journal.pone.0002696.s006 (2.44 MB
TXT)
Data File S2 995 intrinsic genes shown in figure 2. An intrinsic
gene identifier algorithm was used to select a set of intrinsic
scleroderma genes. A gene was considered ‘intrinsic’ if it showed
the most consistent expression between forearm-back pairs and
technical replicates for the same patient, but had the highest
variance in expression across all samples analyzed.
Found at: doi:10.1371/journal.pone.0002696.s007 (0.59 MB
TXT)
Data File S3 Supporting data file for figure 5F. Genes the
differentiate dSSc group 1 vs. group 2
Found at: doi:10.1371/journal.pone.0002696.s008 (0.09MBTDS)
Data File S4 Supporting data file for figure 6. Included are the
177 genes correlated with modified rodnan skin score.
Found at: doi:10.1371/journal.pone.0002696.s009 (0.10 MB
TXT)
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